March-April 2017


Glioma Imaging in the Era of Antiangiogenic Therapy

Farid pic

Nikdokht Farid

In the rapidly evolving landscape of postsurgical, postradiation therapeutic strategies for patients with glioblastoma (GBM), including cytotoxic chemotherapy, antiangiogenic therapy, and immune therapy, bevacizumab has been established as a primary therapeutic option for recurrent GBM1,2 and has also shown substantial promise in the setting of … more »


Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas

Daniels pic

Dianne Daniels

Our group has previously introduced delayed-contrast MR imaging for calculating treatment-response-assessment maps (TRAMs) in patients with brain tumors undergoing standard treatments, providing a clear separation between an active tumor and treatment effects.1,2 Following this application of the TRAMs methodology to aid patient management and decision-making … more »


Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy

Kovanlikaya pic

Ilhami Kovanlikaya

Glioblastoma (GBM) is the most common aggressive primary brain tumor. Despite an aggressive multimodal treatment approach that includes surgical resection and chemoradiation, median survival is limited to approximately 14 months.1

Until recently, there was no standard treatment for recurrent disease after combined chemotherapy and radiation treatment. … more »